 |
|
|
 Christoph U. Correll, MD
Christoph U. Correll, MD is a research psychiatrist at The Zucker Hillside Hospital in Glen Oaks, N.Y., and assistant professor of psychiatry and behavioral sciences at the Albert Einstein College of Medicine, Bronx, N.Y. He also is the medical director at the Zucker Hillside Hospital's Recognition and Prevention (RAP) Program, and the director of the Adverse Events Assessment and Prevention Unit and the Core Laboratory Unit, at the Zucker Hillside Hospital Advanced Center for Intervention and Services Research in Glen Oaks, New York.
Dr. Correll completed his medical studies at both the Free University of Berlin, and Dundee University Medical School in Scotland. After finishing his general psychiatry residency at The Zucker Hillside Hospital in Glen Oaks, N.Y., he trained in child and adolescent psychiatry at Schneider Children's Hospital in New Hyde Park, N. Y. Dr. Correll is a diplomate in both psychiatry and child and adolescent psychiatry for the American Board of Neurology and Psychiatry.
Dr. Correll's research and clinical work focus is on the early identification and treatment of mood disorders and schizophrenia, the psychotic and the bipolar prodrome, as well as the risk-benefit evaluation of psychotropic medications at all illness stages. He has authored or coauthored papers on these topics, serves as a current member of American Psychiatric Association Work Group on Diabetes and Second-generation Antipsychotic Agents and is a reviewer for many scientific journals, including Archives of General Psychiatry, American Journal of Psychiatry, Biological Psychiatry, Journal of Clinical Psychiatry, Journal of the American Academy of Child and Adolescent Psychiatry, Neuropsychopharmacology and Schizophrenia Research.
 Robert L. Findling, MD
Dr. Findling is the Director of the Division of Child and Adolescent Psychiatry at University Hospitals Case Medical Center. He is also a Professor of Psychiatry and Pediatrics at Case Western Reserve University. Dr. Findling earned his undergraduate degree at Johns Hopkins University and went to medical school at the Medical College of Virginia. Dr. Findling did a joint residency-training program in Pediatrics, Psychiatry, and Child & Adolescent Psychiatry at Mt. Sinai Hospital in New York City.
Dr Findling's research endeavors have focused on pediatric psychopharmacology and psychotic disorders in the young. He has extensive experience in pharmacokinetic studies of psychotropic agents in pediatric patients. Dr Findling's research is currently supported in part by the NIMH, NICHD, the Stanley Medical Research Institute, the American Foundation for Suicide Prevention, the St. Luke's Foundation of Cleveland, Ohio and the pharmaceutical industry. In addition, Dr. Findling is a Fellow of the American Academy of Pediatrics and is a member of the American Academy of Child and Adolescent Psychiatry's (AACAP) Work Group on Research.
 Linmarie Sikich, MD
Linmarie Sikich, MD is an Associate Professor in the Division of Child and Adolescent Psychiatry and Division TEACCH, Department of Psychiatry at the University of North Carolina at Chapel Hill. She is director of ASPIRE Research Program, which focuses on developing and rigorously evaluating treatments for psychiatric and neurodevelopmental disorders affecting children and adolescents and their families. She is currently doing research evaluating 1) lithium as a treatment for youth with bipolar disorder, 2) various antipsychotics for treating psychosis and 3) strategies to reduce weight gain in youth who are treated with antipsychotics.
|
|
It is the policy of the Semel Institute for Neuroscience and Human Behavior at UCLA to ensure balance, independence, objectivity, and scientific rigor in all its individually sponsored or jointly sponsored education programs. All faculty participating in the Semel Institute's sponsored CME programs is expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. Its only intent is to openly identify potential conflicts of interest so those program participants may form their own judgments about the presentation with the full disclosure of the facts. It remains for the audience to determine whether the speaker's outside interests may reflect a possible bias in either the exposition or the conclusions presented.
Christoph U. Correll, MD
Speakers’ Bureau: AstraZeneca, Bristol-Myers Squibb, Otsuka America Pharmaceutical, Janssen
Consultant: AstraZeneca, Bristol-Myers Squibb, Otsuka America Pharmaceutical, Eli Lilly, Intracellular Therapeutics, Solvay, Supernus Pharmaceuticals
Robert L. Findling, MD
Grant/Research Support: Abbott, AstraZeneca, Bristol-Myers Squibb, Celltech-Medeva, Forest, GlaxoSmithKline, Johnson & Johnson, Lilly, New River, Novartis, Otsuka America Pharmaceutical, Pfizer, Shire, Solvay, Wyeth
Consultant: Abbott, AstraZeneca, Bristol-Myers Squibb, Celltech-Medeva, Cypress Biosciences, Forest, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, New River, Novartis, Otsuka America Pharmaceutical, Pfizer, Sanofi-Aventis, Sepracore, Shire, Solvay, Supernus Pharmaceuticals
Speakers’ Bureau: Johnson & Johnson, Shire
Linmarie Sikich, MD
Research Support: Pfizer, Janssen, Lilly, Bristol-Myers Squibb, Otsuka America Pharmaceuticals
Wendy Gloffke, PhD
Medical Writer: Nothing to Disclose
The employees of ArcMesa Educators have no financial relationships to disclose.
Printer settings may vary. Please use landscape layout option.
| |
